Adjuvant Therapy With Dabrafenib Plus Trametinib May Provide Benefit in Melanoma

Share this content:
Investigators randomly assigned 870 patients with advanced melanoma who had undergone complete resection to receive trametinib and dabrafenib vs placebo for 1 year.
Investigators randomly assigned 870 patients with advanced melanoma who had undergone complete resection to receive trametinib and dabrafenib vs placebo for 1 year.

Dabrafenib plus trametinib adjuvant therapy significantly lowered the risk of recurrence in patients with BRAFV600E or V600K –mutation positive stage III melanoma compared with placebo, according to a study published in The New England Journal of Medicine.1

Complete resection is the standard therapy for patients with early-stage melanoma, leading to 5-year survival rates of 98% for stage I and 90% for stage II. Patients with advanced melanoma, however, have much higher rates of recurrence even after resection, as there is regional involvement at diagnosis.

For the phase 3 COMBI-AD study (ClinicalTrials.gov Identifier: NCT01682083), investigators randomly assigned 870 patients with advanced melanoma with BRAFV600E/K mutations who had undergone complete resection to receive oral trametinib 2 mg once daily and dabrafenib 150 mg twice daily vs placebo for 1 year. The median follow-up was 2.8 years.

Patients who received adjuvant therapy with dabrafenib and trametinib had an estimated 3-year rate of relapse-free survival of 58% vs 39% in patients who received placebo (hazard ratio [HR], 0.47; 95% CI, 0.39-0.58; P < .001).

The 3-year overall survival rate in the combination therapy arm and placebo arm was 86% and 77%, respectively (HR, 0.57; 95% CI, 0.42-0.79; P = .0006), but did not meet the pre-specified interim analysis boundary of P = .000019 to meet statistical significance.

The combination group also had higher rates distant metastasis-free survival.

Frequently reported adverse events (AEs) included pyrexia, fatigue, nausea/vomiting, diarrhea, arthralgia, rash, and headache, and were consistent with reported rates of AEs from previous studies.

Reference

  1. Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017 Sep 10. doi: 10.1056/NEJMoa1708539 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters